Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
20 hedge funds and large institutions have $3.76M invested in Interpace Biosciences, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
18% more capital inflows, than outflows
Capital inflows: $643K | Capital outflows: $545K
11% more funds holding
Funds holding: 18 → 20 (+2)
0.24% more ownership
Funds ownership: 16.18% → 16.42% (+0.24%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$471K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$45K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.2K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$36.1K |
| 5 |
VF
Virtu Financial
New York
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schonfeld Strategic Advisors
New York
|
-$240K |
| 2 |
JP Morgan Chase
New York
|
-$194K |
| 3 |
Millennium Management
New York
|
-$57K |
| 4 |
Jane Street
New York
|
-$36K |
| 5 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$17.3K |
IDXG Hedge Fund Activity: Q4 2018 in Review
20 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2018, worth a combined $3.76M — down 47% from $7.02M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IDXG positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Perkins Capital Management, adding an estimated $471K. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $240K.
- 20 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2018, up from 18 in Q3 2018.
- Funds reported $3.76M of Interpace Biosciences, Inc. Common Stock stock for Q4 2018, down 47% quarter-over-quarter.
- 5 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2018 and 3 closed out, a net change of +2 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2018 was Perkins Capital Management, an estimated $471K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2018 was Schonfeld Strategic Advisors, an estimated $240K sold.
Based on aggregated 13F filings for Q4 2018.